To view this email as a web page, click here

Today's Rundown

Featured Story

COVID-19 vaccine CEOs vow to wait for phase 3 data before filing for approval

The CEOs of all the leading Western developers of COVID-19 vaccines have vowed to only file for FDA approval after demonstrating safety and efficacy in phase 3. The pledge comes amid reports that the Trump Administration is pushing for a vaccine to be approved before the November election. 

read more

Top Stories

How will COVID-19 vaccines be allocated? AHIP has some questions

Will healthcare workers be among the first in line once a COVID-19 vaccine is available? Will disease outbreaks be taken into account as vaccines are distributed? Exactly how will they be paid for to ensure they are available and accessible? Those are just among the questions raised by America's Health Insurance Plans (AHIP) regarding a preliminary framework for the equitable allocation of COVID-19 vaccines. 

read more

LabCorp to launch single home swab test spanning COVID-19, the flu & RSV

LabCorp announced plans to launch a new at-home COVID-19 diagnostic that allows people to also get tested for the flu and respiratory syncytial virus from a single sample.

read more

Moderna, facing high expectations and fierce competition, won't meet Wall Street's COVID estimates: analyst

Moderna and its investors amid the COVID-19 pandemic, starting with initial vaccine research back in January and progressing to a phase 3 trial this summer at record speed. Now, analysts with SVB Leerink think challenges and competition lie ahead, and they're cautioning investors to the risks.  

read more

Healthcare tracker: Senate to vote as early as this week on 'targeted' COVID-19 relief

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

read more

Biopharma roundup: Rival shots may take a bite out of Moderna's vaccine sales, analyst says; late-stage data on Moderna, Pfizer's shots unlikely before year-end: Fauci

Moderna's vaccine may not meet Wall Street sales projections, one analyst said; plus, phase 3 data on Moderna and Pfizer's shots are unlikely to arrive before election day, Anthony Fauci said. Six Sanofi trials have taken a blow from COVID-19, GlobalData found. LabCorp plans to launch an at-home test for COVID-19 and other respiratory viruses.

read more

Catapult Health launches at-home preventive checkup service for employers

Capitalizing on the demand for remote care solutions, Catapult Health has launched a virtual checkup program for employers that offers home-based preventive care for employees and family members. The service provides virtual checkups using telehealth, clinical diagnostic tools, and screenings for depression and COVID-19.

read more

CSL plots millions of doses of COVID-19 vaccine shots, including AstraZeneca's, for Aussie government

Looking to secure enough doses of a COVID-19 vaccine frontrunner for its residents, the Australian government signed an expansive supply deal with British drugmaker AstraZeneca last month. The Aussies then tapped local drugmaker CSL to chip in on production—and the initial order will tally up to the tens of millions of jabs. 

read more

AstraZeneca puts COVID-19 spin on heart disease awareness, Brilinta campaigns

Too many heart attack victims are not going to the hospital out of fear of catching COVID-19—and that's a problem AstraZeneca wants to fix. A new public service announcement starring celebrity spokesperson and heart attack survivor Bob Harper encourages viewers to call 911 at the first signs of heart attack symptoms. 

read more

Sanofi's later-stage trials hardest hit by COVID-19: report

Sanofi’s trials and attempts at getting new drugs and vaccines against the pandemic onto the market have been some of the hardest hit by COVID-19.

read more